Quick Facts for Rafinlar 75mg Capsule
- Chemical Class
- Sulfanilides
- Habit Forming
- No
- Therapeutic Class
- ANTI NEOPLASTICS
- Action Class
- BRAF inhibitor
Composition of Rafinlar 75mg Capsule
- Dabrafenib (75mg)
Uses of Rafinlar 75mg Capsule
- Treatment of Malignant melanoma
Side Effects of Rafinlar 75mg Capsule
- Fever
- Headache
- Hyperkeratosis
- Palmar-plantar erythrodysesthesia syndrome
- Hair loss
- Joint pain
- Papilloma
Safety Advice for Rafinlar 75mg Capsule
- Alcohol (CONSULT YOUR DOCTOR): It is not known whether it is safe to consume alcohol with Rafinlar 75mg Capsule. Please consult your doctor.
- Pregnancy (CONSULT YOUR DOCTOR): The safety of Rafinlar 75mg Capsule during pregnancy has not been established. There are no adequate and well-controlled studies in pregnant women, and animal data on reproductive toxicity are insufficient. Your doctor will weigh the benefits and any potential risks before prescribing.
- Breast Feeding (CONSULT YOUR DOCTOR): Rafinlar 75mg Capsule may be unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. It should be used only if the expected benefit outweighs the potential risk. Please consult your doctor.
- Driving (UNSAFE): Rafinlar 75mg Capsule may decrease alertness, affect your vision, or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
- Kidney (CAUTION): Rafinlar 75mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment may be needed.
- Liver (CAUTION): Rafinlar 75mg Capsule should be used with caution in patients with liver disease. Dose adjustment may be needed.
Rafinlar 75mg Capsule
Inclusive of all taxes
Free Express Secure Delivery
Protective climate-sealed dispatch across India within 4 to 24 hours.
Order through WhatsAppFinancial Assistance Available
Contact our oncology support team to check your eligibility for manufacturer patient assistance programs (PAP) for Rafinlar 75mg Capsule.
About this medicine
Rafinlar 75mg Capsule (Dabrafenib (75mg))is a prescription oncology medicine. Below is educational product information — follow your doctor's advice for dose and use.
Rafinlar 75mg Capsule should be taken at least 1 hour before or 2 hours after a meal in the dose as advised by the doctor. The duration of treatment varies on the basis of your response to the treatment. Your doctor may advice regular eye examinations while taking this medicine. You must inform the doctor if you experience eye irritation, blurred vision, eye pain, or other vision changes during your treatment. The most common side effects of this medicine include diarrhea, fever, nausea, and headache. If they do not go away or get worse, tell your doctor. There may be ways of preventing or reducing these effects. It is very strong medicine and some people may develop serious side effects while taking it. It may lower your ability to fight infections and lead to problems with your blood, liver, or kidneys. Inform your doctor if you notice unusual bleeding or bruising, lack of energy, loss of appetite, and yellowing of eyes. Your doctor will advise you regular blood tests to check for these. Before taking This medicine, tell your doctor if you have liver or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine, so let your doctor know about all the medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during the treatment with this drug is important to avoid pregnancy. There is a Patient Support Program/Patient Assistance Program available in India for this medicine, being managed by Tata 1mg. Please contact your prescribing doctor to know more about the same. You may also call on (1800-102-1618) for more details.
Quick Facts
Generic Name
Dabrafenib (75mg)
Dosage Form
Capsule
Prescription Status
Doctor's Rx Required
Uses of Rafinlar 75mg Capsule
Side Effects of Rafinlar 75mg Capsule
Oncology medicines should be administered strictly under medical supervision. Inform your oncologist immediately if you experience adverse symptoms.
Clinical Safety Advice for Rafinlar 75mg Capsule
Follow expert clinical guidelines regarding interactions, precautions, and medical conditions when taking Rafinlar 75mg Capsule.
It is not known whether it is safe to consume alcohol with Rafinlar 75mg Capsule. Please consult your doctor.
The safety of Rafinlar 75mg Capsule during pregnancy has not been established. There are no adequate and well-controlled studies in pregnant women, and animal data on reproductive toxicity are insufficient. Your doctor will weigh the benefits and any potential risks before prescribing.
Rafinlar 75mg Capsule may be unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. It should be used only if the expected benefit outweighs the potential risk. Please consult your doctor.
Rafinlar 75mg Capsule may decrease alertness, affect your vision, or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Rafinlar 75mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment may be needed.
Rafinlar 75mg Capsule should be used with caution in patients with liver disease. Dose adjustment may be needed.
Storage & Delivery Protocol
Preservation and climate-safe dispatch guidelines for Rafinlar 75mg Capsule across India.
Storage Conditions
Store in the original container at room temperature below 30°C (86°F). Protect from moisture and direct sunlight. Keep out of reach of children and pets. This medication does not require 2°C–8°C cold-chain refrigeration.
Climate-Sealed Transit
Dispatched in protective, tamper-evident and moisture-sealed packaging.
Rx Verification
Prescription and genuine batch validated prior to dispatch.
Frequently Asked Questions
Clinical Overview: Rafinlar 75mg Capsule
Rafinlar 75mg Capsule contains Dabrafenib, a targeted kinase inhibitor medication. It is specifically designed to treat certain types of cancers that carry an abnormal 'BRAF' gene mutation, helping to block the signals that drive cancer cell proliferation.
How It Works (Mechanism of Action)
Rafinlar works by targeting and inhibiting mutated forms of the BRAF kinase enzyme. In tumors with a BRAF V600 mutation, this enzyme over-signals and causes cancer cells to multiply rapidly. By blocking this specific pathway, Rafinlar helps slow down or stop the growth of the tumor.
Therapeutic & Treatment Context
Oncologists prescribe Rafinlar for patients with unresectable or metastatic melanoma, BRAF-mutated non-small cell lung cancer (NSCLC), and certain cases of advanced thyroid cancer that harbor the specific V600 mutation.
Important Clinical Information & Precautions
Rafinlar is a prescription-only specialty cancer medication and should be initiated and monitored by a qualified medical oncologist. It is frequently prescribed in combination with another targeted therapy (such as Trametinib) depending on the specific cancer type. Regular skin checks are recommended during treatment due to the risk of new skin lesions.
Storage & Safe Handling Instructions
Store in the original container at room temperature below 30°C (86°F). Protect from moisture and direct sunlight. Keep out of reach of children and pets. This medication does not require 2°C–8°C cold-chain refrigeration.
Dosage & Administration Guidelines
The capsules should be swallowed whole with water, ideally taken at least 1 hour before or 2 hours after a meal, maintaining a consistent schedule approximately 12 hours apart. Do not chew, crush, or open the capsules.
Authoritative References & Medical Sources
- FDA Prescribing Information for Dabrafenib (Rafinlar)US FDAView Source
- NCCN Clinical Practice Guidelines in Oncology: Melanoma and NSCLCNCCNView Source
Medical information standards
Educational product information for Rafinlar 75mg Capsule. Not a substitute for advice from your treating doctor or healthcare provider.
- Reviewed by
- Nitin Kumar, D.Pharm (UPPC Reg: 63405)Lead Registered Pharmacist · 11 years clinical experience · Drug licence RLF21DL2025001406, RLF20DL2025001420. See our medical review policy.
- Content dates
- Catalogue copy is re-checked under our editorial standards. Pricing and stock update more often at checkout.
- Business address
- Vyloo Technologies Pvt. Ltd.
10251, F/F, Library Road, Nawab Ganj, Delhi G.P.O., Delhi, North Delhi- 110006, Delhi, IndiaGSTIN 07AAKCV0933E1ZF, 09AAKCV0933E1ZB. More on our drug licence page.
Authoritative references
- CDSCO (India) — Central Drugs Standard Control Organisation — Indian drug regulator
- Ministry of Health & Family Welfare — Government of India health ministry
- WHO Essential Medicines — World Health Organization essential medicines lists
- National Health Portal (India) — Government of India National Health Portal
Have questions about your cancer prescription?
Our licensed oncology pharmacists are available to assist with medicine availability, cold-chain handling, and prescription verification.